- Home
- FGNX vs INO Comparison
FGNX vs INO Comparison
Compare FGNX & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | INO |
|---|---|---|
| Founded | 1932 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.4M | 116.1M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | FGNX | INO |
|---|---|---|
| Price | $1.72 | $1.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.50 | ★ $9.00 |
| AVG Volume (30 Days) | 463.6K | ★ 1.1M |
| Earning Date | 03-26-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,450,000.00 | $182,337.00 |
| Revenue This Year | $95.83 | N/A |
| Revenue Next Year | $42.41 | $23,060.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 144.71 | N/A |
| 52 Week Low | $1.59 | $1.30 |
| 52 Week High | $41.25 | $2.98 |
Technical Indicators
Market Signals| Indicator | FGNX | INO |
|---|---|---|
| Relative Strength Index (RSI) | 25.03 | 44.12 |
| Support Level | $1.59 | $1.56 |
| Resistance Level | $2.98 | $1.78 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 9.22 | 38.26 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.